Recruiting Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors NCT03866382 Conditions Adenocarcinoma, Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, +71 more Locations University of Alabama at Birmingham Cancer Center — Birmingham, Alabama, United States Anchorage Associates in Radiation Medicine — Anchorage, Alaska, United States Anchorage Radiation Therapy Center — Anchorage, Alaska, United States Alaska Breast Care and Surgery LLC — Anchorage, Alaska, United States View all 582 locations View more locations Show fewer locations Loading locations... View Trial Details
Active, Not Recruiting Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic NCT02721732 Conditions Adenocarcinoma, Adrenal Cortex Diseases, Adrenal Cortex Neoplasms, +59 more Locations M D Anderson Cancer Center — Houston, Texas, United States View Trial Details
Active, Not Recruiting Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer NCT03587662 Conditions Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +18 more Locations M D Anderson Cancer Center — Houston, Texas, United States View Trial Details
